Protara Therapeutics Business Summary

Protara Therapeutics, Inc. (TARA) is a clinical-stage biopharmaceutical company that operates on a research-and-development-intensive business model, currently generating revenue primarily through interest income and strategic financing rather than product sales. The company’s primary business segments are focused on oncology and rare diseases, specifically advancing its lead cell-based therapy, TARA-002, for Non-Muscle Invasive Bladder Cancer (NMIBC) and Lymphatic Malformations (LMs), alongside IV Choline Chloride for Intestinal Failure Associated Liver Disease (IFALD). Protara positions itself as a high-conviction catalyst play within the biotechnology sector, leveraging a robust cash runway extended into 2028 via recent public offerings. Its direct competitors include Trevi Therapeutics, uniQure, and Sana Biotechnology; relative to these peers, Protara occupies a specialized niche by targeting underserved patient populations with transformative substrate replacement and immunostimulant therapies. The company was co-founded by Jesse Shefferman and Dr. Jacqueline Zummo, both of whom maintain central leadership roles. Jesse Shefferman serves as Chief Executive Officer and President, bringing a pedigree from Retrophin, Vertex Pharmaceuticals, and investment banking roles at Barclays and Lehman Brothers. Dr. Jacqueline Zummo, the Chief R&D Officer as of February 2026, possesses over 15 years of biopharmaceutical experience in streamlining clinical development and regulatory strategy. The executive team is further bolstered by Chief Commercial Officer William “Bill” Conkling, formerly CEO of Rafael Holdings, and Chief Medical Officer Dr. Leonardo Viana Nicacio. Protara is supported by a high-profile board chaired by Luke Beshar, former CFO of NPS Pharmaceuticals, and maintains significant institutional backing from major investors including Janus Henderson Group, BlackRock, and Vanguard.